Search results for "small intestine"

showing 10 items of 94 documents

Disturbance of hepatic and intestinal microcirculation in experimental liver cirrhosis

2005

AIM: To analyze hepatic, mesenteric and mucosal microcirculation and leukocyte-endothelium interaction (LEI) in a rat model with liver cirrhosis. METHODS: Hepatic cirrhosis was induced in Wistar rats by gavage with carbon tetrachloride, and intravital videomicroscopy was performed in liver, mesentery and small intestine mucosa. Special emphasis is given on microcirculatory and morphometric changes during cirrhotic portal hypertension. RESULTS: LEI was influenced significantly in the cirrhotic liver but not in the gut. Blood flow measurement showed significant differences among liver, main mesenteric vessels and the mucosa. The results of our study indicate that liver cirrhosis leads to alte…

Malemedicine.medical_specialtyCirrhosisAntithrombin IIILiver Cirrhosis ExperimentalGastroenterologyMicrocirculationInternal medicineIntestine SmallmedicineAnimalsSplanchnic CirculationRats WistarMesenteryBlood CoagulationFibrous capsule of GlissonMicroscopy Videobusiness.industryMicrocirculationAntithrombinGastroenterologyGeneral MedicineBlood flowmedicine.diseaseSmall intestineRatsmedicine.anatomical_structureLiverPortal hypertensionBrief Reportsbusinessmedicine.drugLiver Circulation
researchProduct

Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet.

2013

Endogenous glucagon-like peptide-2 (GLP2) is a key mediator of refeeding-induced and resection-induced intestinal adaptive growth. This study investigated the potential role of GLP2 in mediating the mucosal responses to a chronic high-fat diet (HFD). In this view, the murine small intestine adaptive response to a HFD was analyzed and a possible involvement of endogenous GLP2 was verified using GLP2 (3–33) as GLP2 receptor (GLP2R) antagonist. In comparison with animals fed a standard diet, mice fed a HFD for 14 weeks exhibited an increase in crypt–villus mean height (duodenum, 27.5±3.0%; jejunum, 36.5±2.9%;P<0.01), in the cell number per villus (duodenum, 28.4±2.2%; jejunum, 32.0±2.9%;P&l…

Malemedicine.medical_specialtyDuodenumEndocrinology Diabetes and MetabolismEndogenyBiologyDiet High-Fatdigestive systemJejunumMiceEndocrinologyInternal medicineIntestine SmallmedicineGlucagon-Like Peptide 2Receptors GlucagonAnimalsMolecular Targeted TherapyObesityIntestinal MucosaReceptorCell ProliferationCell growthdigestive oral and skin physiologyGLP2 receptor expression intestinal morphometry obesity intestinal adaptationGlucagon-like peptide-2Adaptation PhysiologicalSmall intestinePeptide FragmentsUp-RegulationMice Inbred C57BLEndocrinologymedicine.anatomical_structureJejunumKi-67 AntigenDuodenumGlucagon-Like Peptide-2 ReceptorAnti-Obesity AgentsGlucagon-Like Peptide-2 ReceptorSignal TransductionThe Journal of endocrinology
researchProduct

The influence of active secretion processes on intestinal absorption of salbutamol in the rat.

2001

Abstract Salbutamol was perfused in the small intestine of rat using a standard rat gut ‘in situ’ preparation: (1) in inhibitor-free solution at seven different concentrations (0.15, 0.29, 1.20, 5.0, 9.0, 13.0 and 18.0 mM); (2) at a 0.29 mM concentration – thought to be close to the allometric dose in man – in the presence of a non-specific enzyme inhibitor, sodium azide (0.3, 3.0 and 6.0 mM); and (3) at 0.29 mM in the presence of a selective secretion inhibitor, verapamil (10.0 and 20.0 mM). In free solution, the mixed-order rate constants, k ′ a , of salbutamol increase as the solute concentration increases until an apparent asymptotic value is reached. This could be due to the saturation…

Malemedicine.medical_specialtyEnterocytePharmaceutical ScienceIntestinal absorptionchemistry.chemical_compoundInternal medicinemedicineAnimalsAlbuterolATP Binding Cassette Transporter Subfamily B Member 1Rats WistarSodium AzidebiologyDose-Response Relationship DrugChemistryGeneral MedicineAdrenergic beta-AgonistsSmall intestineBioavailabilityRatsEndocrinologymedicine.anatomical_structureIntestinal AbsorptionVerapamilEnzyme inhibitorSalbutamolbiology.proteinVerapamilSodium azideBiotechnologymedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Modulation by NO of acetylcholine release in the ileum of wild-type and NOS gene knockout mice.

2002

Nitric oxide (NO) inhibits the release of acetylcholine and cholinergic contractions in the small intestine of several species, but no information is available about the mouse ileum. This study examines the effects of NO on the electrically evoked release of [3H]acetylcholine and smooth muscle contraction in myenteric plexus-longitudinal muscle preparations of wild-type mice and of neuronal NO synthase (nNOS) and endothelial NOS (eNOS) knockout mice. The NOS inhibitor N G-nitro-l-arginine (l-NNA) and the guanylyl cyclase inhibitor 1 H-[1,2,4]oxadiazolo[4,3-α]quinoxalin-1-one (ODQ) concentration dependently increased the evoked [3H]acetylcholine release and cholinergic contractions in prepa…

Malemedicine.medical_specialtyNitric Oxide Synthase Type IIIPhysiologyNitric Oxide Synthase Type IIIleumNitric Oxide Synthase Type IBiologyIn Vitro TechniquesNitric OxideNitroarginineNitric oxidechemistry.chemical_compoundMiceIleumPhysiology (medical)Internal medicineQuinoxalinesmedicineAnimalsNitric Oxide DonorsEnzyme InhibitorsGene knockoutMice KnockoutOxadiazolesHepatologyPenicillamineGastroenterologyNitric Oxide Synthase Type IIISmall intestineAcetylcholineElectric StimulationNitric oxide synthaseEndocrinologymedicine.anatomical_structurechemistrybiology.proteinCholinergicNitric Oxide SynthaseGastrointestinal MotilityAcetylcholinemedicine.drugAmerican journal of physiology. Gastrointestinal and liver physiology
researchProduct

Formation and release of acetylpyrrolidinecholine (N-methyl, N-acetoxyethylpyrrolidinium) as a false cholinergic transmitter in the myenteric plexus …

1977

1. Longitudinal muscle strips of the guineapig small intestine were incubated with Tyrode solution containing the choline analogue pyrrolidinecholine. At the end of the incubation the concentrations of acetylcholine and its analogue acetylpyrrolidinecholine were determined in the strips by gas chromatography. 2. After 120 min of incubation with 1 mM pyrrolidinecholine, acetylpyrrolidinecholine comprised about 15% of the total amount of acetylcholine plus acetylpyrrolidinecholine. Electrical stimulation (1 Hz) of the strips during the incubation slightly increased the proportion of acetylpyrrolidinecholine to 21%. 3. The acetylcholine content of control strips increased significantly during …

Malemedicine.medical_specialtyPyrrolidinesTime FactorsGuinea PigsMyenteric PlexusStimulationIn Vitro TechniquesGuinea pigchemistry.chemical_compoundInternal medicineIntestine SmallmedicineCholineAnimalsIncubationMyenteric plexusPharmacologyChemistryParasympatholyticsGeneral MedicineSmall intestineAcetylcholineElectric StimulationMuscle DenervationEndocrinologymedicine.anatomical_structureCholinergicFemaleAcetylcholinemedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Effect of vasoactive intestinal polypeptide on the release of serotonin from the in vitro vascularly perfused small intestine of guinea pig.

1989

Isolated segments of the guinea pig small intestine were vascularly perfused and the release of endogenous serotonin (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) into the portal vein was measured. All test substances were intraarterially perfused. Vasoactive intestinal polypeptide (VIP, 1 pmol/l-100 nmol/l) inhibited the spontaneous release of 5-HT and 5-HIAA. The maximal inhibitory effect (about 60%) was seen at 100 pmol/l. The effect of VIP on the spontaneous release of 5-HT and 5-HIAA was not changed in the presence of 1 mumol/l tetrodotoxin (TTX). Raising intraluminal pressure by 500 Pa for 5 min increased the release of 5-HT and 5-HIAA by about 25%. Raising the intralu…

Malemedicine.medical_specialtySerotoninMetaboliteVasoactive intestinal peptideGuinea PigsTetrodotoxinBiologyIn Vitro TechniquesGuinea pigchemistry.chemical_compoundInternal medicineIntestine SmallmedicineAnimalsPharmacologyMuscle SmoothGeneral MedicineHydroxyindoleacetic AcidSmall intestineEndocrinologymedicine.anatomical_structurenervous systemGastrointestinal hormonechemistryEnterochromaffin cellTetrodotoxinSerotoninhormones hormone substitutes and hormone antagonistsMuscle ContractionVasoactive Intestinal PeptideNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Dental and oral manifestations of celiac disease

2018

Background The objective of this study was to evaluate the dental and oral manifestations in patients with celiac disease. Material and Methods The sample consisted of 40 patients with the disease and 40 without the disease matched by age in southern Brazil. The CD group included patients previously diagnosed by positive anti-endomysial (IgA) examination and confirmed by small intestine biopsy. The presence of dental enamel defects and dental caries was evaluated by a calibrated researcher according to AINE’s and WHO’s criteria, respectively. The history of recurrent aphthous ulcers and dry mouth was obtained through reporting. For the evaluation of the salivary flow, the saliva samples wer…

MolarMaleSalivaAdolescentDentistryDisease03 medical and health sciences0302 clinical medicinestomatognathic systemmedicinePrevalenceHumansIn patientChildGeneral DentistryPermanent teethOral Medicine and Pathologybusiness.industryResearch030206 dentistrySmall intestine biopsyDry mouth:CIENCIAS MÉDICAS [UNESCO]stomatognathic diseasesCeliac DiseaseOtorhinolaryngologyTooth DiseasesUNESCO::CIENCIAS MÉDICASOral examination030211 gastroenterology & hepatologySurgeryFemalemedicine.symptombusinessMouth DiseasesMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Synthesis and evaluation of fluorine-18 labeled glyburide analogs as β-cell imaging agents

2003

Glyburide is a prescribed hypoglycemic drug for the treatment of type 2 diabetic patients. We have synthesized two of its analogs, namely N-[4-[beta-(2-(2'-fluoroethoxy)-5-chlorobenzenecarboxamido)ethyl]benzenesulfonyl]-N'-cyclohexylurea (2-fluoroethoxyglyburide, 8b) and N-[4-[beta-(2-(2'-fluoroethoxy)-5-iodobenzenecarboxamido)ethyl]benzenesulfonyl]-N'-cyclohexylurea (2-fluoroethoxy-5-deschloro-5-iodoglyburide, 8a), and their fluorine-18 labeled analogs as beta-cell imaging agents. Both F-18 labeled compound 8a and compound 8b were synthesized by alkylation of the corresponding multistep synthesized hydroxy precursor 4a and 4b with 2-[(18)F]fluoroethyl tosylate in DMSO at 120 degrees C for …

OctanolFluorine RadioisotopesCancer ResearchBiodistributionMice SCIDAlkylationHigh-performance liquid chromatographyMedicinal chemistryStreptozocinCell LineDiabetes Mellitus ExperimentalIslets of LangerhansMicechemistry.chemical_compoundIn vivoGlyburidemedicineAnimalsTissue DistributionRadiology Nuclear Medicine and imagingRadionuclide ImagingCells CulturedChemistrySmall intestineRatsPartition coefficientmedicine.anatomical_structureBiochemistryOrgan SpecificityIsotope LabelingMolecular MedicineSulfonylurea receptorRadiopharmaceuticalsNuclear Medicine and Biology
researchProduct

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer

2017

Background: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications. In this context, the positron emitter scandium-44 is an attractive alternative for PET imaging. We report the synthesis of [44Sc…

OncologyMalemedicine.medical_specialtytheranostics.Medicine (miscellaneous)Context (language use)SpleenGallium RadioisotopesLutetiumurologic and male genital diseases030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancerHeterocyclic Compounds 1-Ring0302 clinical medicineInternal medicinePositron Emission Tomography Computed TomographyLNCaPmedicineDosimetryHumansRadiometryPharmacology Toxicology and Pharmaceutics (miscellaneous)AgedRadioisotopesUrinary bladderChemistrybusiness.industryDipeptidesProstate-Specific Antigenmedicine.diseaseprostate cancerPSMA-617scandium-44Small intestineProstatic Neoplasms Castration-Resistantmedicine.anatomical_structurePET030220 oncology & carcinogenesisAbsorbed doseRadiopharmaceuticalsNuclear medicinebusinessScandiumResearch PaperHalf-LifeTheranostics
researchProduct

Chirurgische Therapie bei Karzinoiden des Gastrointestinaltraktes

2001

More than 70% of all carcinoids are localized in the gastrointestinal tract. Carcinoids of the upper, middle and lower intestines have to be distinguished ontogenetically. The classification according to Capella takes into account the size of the tumor ( 2 cm), the grade of invasion of other structures, the grade of angioinvasion, the biologic behaviour, the grade of differentiation and the hormonal activity of the tumor. A carcinoid-syndrome is rarely found. Carcinoids of the small intestine occur multiple in 30-50% and in 20-30% a second malignant tumor is seen. In carcinoids of the colon this percentage is even higher (25-40%). The therapy of carcinoids depends on the size of the tumor a…

Oncologyendocrine systemGastrointestinal tractmedicine.medical_specialtyAngioinvasionendocrine system diseasesIleusbusiness.industryCarcinoid tumorsStomachmedicine.diseaseGastroenterologydigestive system diseasesSmall intestineMetastasisSurgical therapymedicine.anatomical_structureInternal medicinemedicineSurgerybusinessneoplasmsZentralblatt für Chirurgie
researchProduct